Gilead Sciences Stock Current Valuation
| GILD Stock | USD 111.53 0.50 0.45% |
Valuation analysis of Gilead Sciences helps investors to measure Gilead Sciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Gilead Sciences' price fluctuation is very steady at this time. Calculation of the real value of Gilead Sciences is based on 3 months time horizon. Increasing Gilead Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gilead stock is determined by what a typical buyer is willing to pay for full or partial control of Gilead Sciences. Since Gilead Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gilead Stock. However, Gilead Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 111.53 | Real 125.0 | Hype 111.53 | Naive 114.2 |
The real value of Gilead Stock, also known as its intrinsic value, is the underlying worth of Gilead Sciences Company, which is reflected in its stock price. It is based on Gilead Sciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Gilead Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Gilead Sciences helps investors to forecast how Gilead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gilead Sciences more accurately as focusing exclusively on Gilead Sciences' fundamentals will not take into account other important factors: Gilead Sciences Company Current Valuation Analysis
Gilead Sciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gilead Sciences Current Valuation | 156.58 B |
Most of Gilead Sciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Gilead Sciences has a Current Valuation of 156.58 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is significantly lower than that of the firm.
Gilead Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is currently under evaluation in current valuation category among its peers.
Gilead Fundamentals
| Return On Equity | 0.0229 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 156.58 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 89.68 % | ||||
| Number Of Shares Shorted | 22.93 M | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 7.19 X | ||||
| Price To Sales | 4.81 X | ||||
| Revenue | 28.75 B | ||||
| Gross Profit | 22.5 B | ||||
| EBITDA | 1.66 B | ||||
| Net Income | 5.61 B | ||||
| Cash And Equivalents | 6.14 B | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 24.99 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 15.45 X | ||||
| Cash Flow From Operations | 10.83 B | ||||
| Short Ratio | 3.43 X | ||||
| Earnings Per Share | 0.38 X | ||||
| Price To Earnings To Growth | 0.59 X | ||||
| Target Price | 107.59 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 138.37 B | ||||
| Total Asset | 62.12 B | ||||
| Retained Earnings | 16.3 B | ||||
| Working Capital | 4.8 B | ||||
| Current Asset | 1.18 B | ||||
| Current Liabilities | 104.89 M | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.76 % | ||||
| Net Asset | 62.12 B | ||||
| Last Dividend Paid | 3.08 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Gilead Sciences Piotroski F Score and Gilead Sciences Altman Z Score analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.